314 related articles for article (PubMed ID: 37600799)
21. Neoadjuvant Programmed Cell Death Protein 1 Blockade Combined With Stereotactic Body Radiation Therapy for Stage III(N2) Non-Small Cell Lung Cancer: A Case Series.
Wang Z; Qiang Y; Shen Q; Zhu XX; Song Y
Front Oncol; 2022; 12():779251. PubMed ID: 35321437
[TBL] [Abstract][Full Text] [Related]
22. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer.
Lanni TB; Grills IS; Kestin LL; Robertson JM
Am J Clin Oncol; 2011 Oct; 34(5):494-8. PubMed ID: 20805737
[TBL] [Abstract][Full Text] [Related]
23. Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review.
Rodríguez Plá M; Dualde Beltrán D; Ferrer Albiach E
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769050
[No Abstract] [Full Text] [Related]
24. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Howington JA; Blum MG; Chang AC; Balekian AA; Murthy SC
Chest; 2013 May; 143(5 Suppl):e278S-e313S. PubMed ID: 23649443
[TBL] [Abstract][Full Text] [Related]
25. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
Kang J; Zhang C; Zhong WZ
Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
Ahern E; Solomon BJ; Hui R; Pavlakis N; O'Byrne K; Hughes BGM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083418
[TBL] [Abstract][Full Text] [Related]
28. A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer.
Mattes MD; Eubank TD; Almubarak M; Wen S; Marano GD; Jacobson GM; Ma PC
Clin Lung Cancer; 2021 Jul; 22(4):268-273. PubMed ID: 33608212
[TBL] [Abstract][Full Text] [Related]
29. The impact of stereotactic body radiation therapy on the overall survival of patients diagnosed with early-stage non-small cell lung cancer.
Amin SA; Alam M; Baine MJ; Meza JL; Bennion NR; Zhang C; Rahman I; Lin C
Radiother Oncol; 2021 Feb; 155():254-260. PubMed ID: 33317997
[TBL] [Abstract][Full Text] [Related]
30. [Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer].
Qi C; Tian P; Li W
Zhongguo Fei Ai Za Zhi; 2024 Feb; 27(2):138-146. PubMed ID: 38453446
[TBL] [Abstract][Full Text] [Related]
31. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
Lee JM; Tsuboi M; Brunelli A
Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
[TBL] [Abstract][Full Text] [Related]
32. Current status of immune checkpoint inhibition in early-stage NSCLC.
Vansteenkiste J; Wauters E; Reymen B; Ackermann CJ; Peters S; De Ruysscher D
Ann Oncol; 2019 Aug; 30(8):1244-1253. PubMed ID: 31143921
[TBL] [Abstract][Full Text] [Related]
33. Rapid Arc-SBRT: Non-Invasive Immune Adjuvant for Advanced Stage Non-Small Cell Lung Carcinoma.
Chairmadurai A; Jain SK; Jain A; Prakash H
Anticancer Agents Med Chem; 2022; 22(2):202-205. PubMed ID: 34225640
[TBL] [Abstract][Full Text] [Related]
34. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study.
Bestvina CM; Pointer KB; Karrison T; Al-Hallaq H; Hoffman PC; Jelinek MJ; Juloori A; Melotek JM; Murgu S; Partouche J; Vokes EE; Weichselbaum RR; Pitroda SP; Patel JD; Chmura SJ
J Thorac Oncol; 2022 Jan; 17(1):130-140. PubMed ID: 34500113
[TBL] [Abstract][Full Text] [Related]
35. The impact of histology in the outcomes of patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) and adjuvant chemotherapy.
Ernani V; Appiah AK; Baine MJ; Smith LM; Ganti AK
Cancer Treat Res Commun; 2020; 24():100197. PubMed ID: 32777751
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.
Uprety D; Mandrekar SJ; Wigle D; Roden AC; Adjei AA
J Thorac Oncol; 2020 Aug; 15(8):1281-1297. PubMed ID: 32522713
[TBL] [Abstract][Full Text] [Related]
37. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline.
Videtic GMM; Donington J; Giuliani M; Heinzerling J; Karas TZ; Kelsey CR; Lally BE; Latzka K; Lo SS; Moghanaki D; Movsas B; Rimner A; Roach M; Rodrigues G; Shirvani SM; Simone CB; Timmerman R; Daly ME
Pract Radiat Oncol; 2017; 7(5):295-301. PubMed ID: 28596092
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report.
Yang RX; Hei Y; Zhu WT; Wang QR; Zhang HM; Chen Y
Curr Oncol; 2022 Aug; 29(9):6203-6210. PubMed ID: 36135056
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the outcomes of stereotactic body radiotherapy versus surgical treatment for elderly (≥70) patients with early-stage non-small cell lung cancer after propensity score matching.
Dong B; Wang J; Zhu X; Chen Y; Xu Y; Shao K; Zheng L; Ying H; Chen M; Cao J
Radiat Oncol; 2019 Nov; 14(1):195. PubMed ID: 31699115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]